Understanding drug resistance for monotherapy treatment of HIV infection

Bulletin of Mathematical Biology

Volumn 59, Issue 4, 1997, Pages 763-785

  Kirschner, Denise E ^a   Webb, G F ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ARTICLE; BIOLOGICAL MODEL; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LYMPHOCYTE COUNT; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MATHEMATICS; T LYMPHOCYTE; VIRUS INFECTIVITY; VIRUS TITRATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0031177707     PISSN: 00928240     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02458429     Document Type: Article

References (30)

1. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 267, 483-489.
2. Concorde Coordinating Committee. 1994. MRC/ANRS randomized double-blind controlled trial of immediate and deferred AZT in symptom-free HIV infection. The Lancet 343, 871-881.
3. Embretson, J. et al. 1993. Analysis of HIV infected tissues by amplification and in situ hybridization reveals latent and permissive infections at single-cell resolution. Proc. Nat. Acad. Sci. 90, 357.
4. Fischl, M. A. et al. 1990. The safety and efficacy of AZT in the treatment of subjects with mildly symptomatic HIV type 1. Annals Int. Med. 112, 727-737.
5. Hamilton, J. D. et al. 1992. A controlled trial of early vs. late treatment with AZT in symptomatic HIV infection. New England J. Med. 326, 437-443.
6. Ho, D. D. et al. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126.
7. Kirschner, D. and A. Perelson. 1995. A model for the immune system response to HIV: AZT treatment studies. In Mathematical Populations Dynamics III, Theory of Epidemics, O. Arino, D. Axelrod and M. Kimmel (Eds), Vol. 1, pp. 295-310. Winnepeg, Man., Canada: Wuerz.
8. Kirschner, D. and G. F. Webb. 1996. A model for treatment strategy in the chemotherapy of AIDS. Bull. Math. Biol. 58, 367-391.
9. Kirschner, D. and G. F. Webb. 1997a. A mathematical model of combined drug therapy of HIV infection. J. Theoret. Med., to appear.
10. Kirschner, D. and G. F. Webb. 1997b. Qualitative differences in HIV chemotherapy between resistance and remission outcomes. Emerging Infect. Dis., to appear.
11. Lafeuillade, A., C. Poggi, N. Profizi et al. 1996. Human immunodeficiency virus type 1 in lymph nodes compared with plasma. J. Infect. Dis. 174, 404-407.
12. Larder, B. A. et al. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243, 1731-1734.
13. + cell counts, and HIV-1 production in cells. Science 271, 670-671.
14. Loveday, C. et al. 1995. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. LANCET 345, 820-824.
15. McLean, A. and M. Nowak. 1992. Competition between AZT sensitive and AZT resistant strains of HIV. AIDS 6, 71-79.
16. McLean, A. et al. 1991. Population dynamics of HIV within an individual after treatment with AZT. AIDS 5, 485-489.
17. McLean, A. R. and M. A. Nowak. 1992. Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV. AIDS 6, 71-79.
18. McLeod, G. X. and S. M. Hammer. 1992. Zidovudine: 5 years later. Annals Int. Med. 117, 487-501.
19. Mohri, H. et al. 1993. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc. Nat. Acad. Sci. USA 90, 25-29.
20. Pantaleo, G., C. Graziosi et al. 1996. HIV infection is active and pregressive in lymphoid tissue during the clinically latent stage of disease. Nature 362, 355-358.
21. Perelson, A. et al. 1996. HIV-1 dynamics in vivo: clearance rate, infected cell lifespan, and viral generation time. Science 271, 1582-1585.
22. + T cells. Math. Biosci. 114, 81-125.
23. Perelson, A. S. 1989. Modeling the interaction of the immune system with HIV. In Mathematical and Statistical Approaches to AIDS Epidemiology, Lect. Notes in Biomath., C. Castillo-Chavez (Ed), Vol. 83, pp. 350-370. New York: Springer-Verlag.
24. Redfield, R. and D. Burke. 1988. HIV infection: the clinical picture. Sci. Amer. 90-98.
25. Richman, D. D. et al. 1990. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J. Acquired Immune Deficiency Syndromes 3, 743-746.
26. Ruffault, A. et al. 1995. The prognostic value of plasma viremia in HIV-infected patients under AXT treatment - a two-year follow-up study. J. AIDS 9, 43-248.
27. Vella, S. et al. 1994. Long-term follow up of AZT therapy in asymptomatic HIV infection: results of a multicenter cohort study. J. AIDS 7, 31-38.
28. Volberding, P. A. et al. 1994. The duration of zidovudine benefit in persons with asymptomatic HIV infection. J. Amer. Med. Assoc. 272, 437-442.
29. Volberding, P. A. et al. 1990. Zidovudine in asymptomatic human immunodeficiency virus infection. New England J. Med. 322, 941-949.
30. Wei, X. et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122.